UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

The New England journal of medicine, 2014-07, Vol.371 (3), p.224-233

2014

Volltextzugriff (PDF)

Reduction of Cancer-Related Fatigue With Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients With Advanced Cancer

Journal of clinical oncology, 2013-09, Vol.31 (25), p.3076-3082

2013

Volltextzugriff (PDF)

Neuroendocrine Tumors: a Relevant Clinical Update

Current oncology reports, 2022-06, Vol.24 (6), p.703-714

2022

Volltextzugriff (PDF)

Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

Journal of clinical oncology, 2008-09, Vol.26 (26), p.4311-4318

2008

Volltextzugriff (PDF)

Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study

The lancet oncology, 2015-06, Vol.16 (6), p.695-703

2015

Volltextzugriff (PDF)

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

Endocrine-related cancer, 2016-03, Vol.23 (3), p.191-199

2016

Volltextzugriff (PDF)

The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas

Pancreas, 2010-08, Vol.39 (6), p.799-800

2010

Volltextzugriff (PDF)

PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

Clinical cancer research, 2012-03, Vol.18 (6), p.1777-1789

2012

Volltextzugriff (PDF)

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

Journal of clinical oncology, 2008-06, Vol.26 (18), p.3063-3072

2008

Volltextzugriff (PDF)

Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience

Cancer research (Chicago, Ill.), 2013-03, Vol.73 (5), p.1449-1453

2013

Volltextzugriff (PDF)

Consensus guidelines for the management and treatment of neuroendocrine tumors

Pancreas, 2013-05, Vol.42 (4), p.557

2013

Volltextzugriff (PDF)

Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population

Pancreas, 2012-04, Vol.41 (3), p.461-466

2012

Volltextzugriff (PDF)

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study

Endocrine, 2021-02, Vol.71 (2), p.502-513

2021

Volltextzugriff (PDF)

Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma

Clinical gastroenterology and hepatology, 2017-11, Vol.15 (11), p.1791-1799

2017

Volltextzugriff (PDF)

Immunotherapy and targeted therapy-the new roadmap in cancer treatment

Annals of translational medicine, 2019-10, Vol.7 (20), p.595-595

2019

Volltextzugriff (PDF)

Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus

The journal of clinical endocrinology and metabolism, 2011-12, Vol.96 (12), p.3741-3749

2011

Volltextzugriff (PDF)

New Strategies for Advanced Neuroendocrine Tumors in the Era of Targeted Therapy

Clinical cancer research, 2012-04, Vol.18 (7), p.1830-1836

2012

Volltextzugriff (PDF)

Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma

Gastroenterology (New York, N.Y. 1943), 2015-07, Vol.149 (1), p.119-129

2015

Volltextzugriff (PDF)

Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors

Pancreas, 2015-03, Vol.44 (2), p.190-197

2015

Volltextzugriff (PDF)

Molecular pathways and targeted therapy in cholangiocarcinoma

Clinical advances in hematology & oncology, 2019-11, Vol.17 (11), p.630-637

2019

Volltextzugriff (PDF)

Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b

Journal of clinical oncology, 2008-03, Vol.26 (8), p.1316-1323

2008

Volltextzugriff (PDF)

Old Drug New Use―Amoxapine and Its Metabolites as Potent Bacterial β-Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity

Clinical cancer research, 2014-07, Vol.20 (13), p.3521-3530

2014

Volltextzugriff (PDF)

Metastatic pancreatic neuroendocrine tumors (pNET): Placing current findings into perspective

Cancer treatment reviews, 2013-02, Vol.39 (1), p.3-9

Phan, Alexandria T

2013

Volltextzugriff (PDF)

Emerging treatment options for patients with gastroenteropancreatic neuroendocrine tumors

Clinical advances in hematology & oncology, 2017-04, Vol.15 Suppl 4 (4), p.10-14

Phan, Alexandria T

2017

Volltextzugriff (PDF)

Epidemiological risk factors for adrenocortical carcinoma: A hospital‐based case–control study

International journal of cancer, 2020-04, Vol.146 (7), p.1836-1840

2020

Volltextzugriff (PDF)

1 – 25 von 161

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(147)
Mit Volltextzugriff
(125)

Publikationsform

Sprache

Englisch
(161)

Erscheinungsjahr

n.n

Thema

Humans
(83)
Science & Technology
(83)
Life Sciences & Biomedicine
(82)
Female
(57)
Oncology
(54)
Male
(52)
Middle Aged
(48)
Aged
(41)
Adult
(36)
Biological And Medical Sciences
(28)
Medical Sciences
(28)
Treatment Outcome
(22)
Tumors
(21)
Neuroendocrine Tumors
(19)
Neuroendocrine Tumors - Drug Therapy
(18)
Retrospective Studies
(18)
Aged, 80 And Over
(16)
Prognosis
(16)
Disease-Free Survival
(15)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

Reduction of Cancer-Related Fatigue With Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients With Advanced Cancer

Neuroendocrine Tumors: a Relevant Clinical Update

Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas

PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience

Consensus guidelines for the management and treatment of neuroendocrine tumors

Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study

Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma

Immunotherapy and targeted therapy-the new roadmap in cancer treatment

Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus

New Strategies for Advanced Neuroendocrine Tumors in the Era of Targeted Therapy

Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma

Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors

Molecular pathways and targeted therapy in cholangiocarcinoma

Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b

Old Drug New Use―Amoxapine and Its Metabolites as Potent Bacterial β-Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity

Metastatic pancreatic neuroendocrine tumors (pNET): Placing current findings into perspective

Emerging treatment options for patients with gastroenteropancreatic neuroendocrine tumors

Epidemiological risk factors for adrenocortical carcinoma: A hospital‐based case–control study

Suchergebnisse filtern